EGFR and neoplasm: EGFR inhibitor erlotinib could suppress the promotion of STARD4 on the progression of HCC, which further reinforced the idea that STARD4 exerts tumor-promoting effects and enhances the resistance to lenvatinib through activation of EGFR/PI3K/AKT pathway in HCC cells.